Definition of the Mamu A*01 peptide binding specificity: Application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins

被引:45
作者
Sidney, J
Dzuris, JL
Newman, MJ
Johnson, RP
Amitinder, K
Walker, CM
Appella, E
Mothe, B
Watkins, DI
Sette, A
机构
[1] Epimmune Inc, San Diego, CA 92121 USA
[2] New England Reg Primate Res Ctr, Southborough, MA 01772 USA
[3] Ohio State Univ, Coll Med & Publ Hlth, Childrens Res Inst, Columbus, OH 43205 USA
[4] NCI, NIH, Bethesda, MD 20892 USA
[5] Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA
关键词
D O I
10.4049/jimmunol.165.11.6387
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Single amino acid substitution analogs of the known Mamu A*01 binding peptide gag 181-190 and libraries of naturally occurring sequences of viral or bacterial origin were used to rigorously define the peptide binding motif associated,vith Mamu A*01 molecules. The presence of S or T in position 2, P in position 3, and hydrophobic or aromatic residues at the C terminus is associated with optimal binding capacity, At each of these positions, additional residues are also tolerated but associated with significant decreases in binding capacity, The presence of at least two preferred and one tolerated residues at the three anchor positions is necessary for good Mamu A*01 binding;, optimal ligand size is 8-9 residues. This detailed motif has been used to map potential epitopes from SIVmac239 regulatory proteins and to engineer peptides with increased binding capacity. A total of 13 wild type and 17 analog candidate epitopes were identified. Furthermore, our analysis reveals a significantly lower than expected frequency of epitopes in early regulatory proteins, suggesting a possible evolutionary- and/or immunoselection directed against variants of viral products that contain CTL epitopes.
引用
收藏
页码:6387 / 6399
页数:13
相关论文
共 57 条
[1]   Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence [J].
Ahlers, JD ;
Takeshita, T ;
Pendleton, CD ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10856-10861
[2]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[3]  
Allen TM, 1998, J IMMUNOL, V160, P6062
[4]  
Almond N M, 1998, AIDS, V12 Suppl A, pS133
[5]  
Bakker ABH, 1997, INT J CANCER, V70, P302, DOI 10.1002/(SICI)1097-0215(19970127)70:3<302::AID-IJC10>3.0.CO
[6]  
2-H
[7]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIF(-) MUTANT PARTICLES FROM RESTRICTIVE CELLS - ROLE OF VIF IN CORRECT PARTICLE ASSEMBLY AND INFECTIVITY [J].
BORMAN, AM ;
QUILLENT, C ;
CHARNEAU, P ;
DAUGUET, C ;
CLAVEL, F .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2058-2067
[8]   T lymphocyte responses in HIV-1 infection: implications for vaccine development [J].
Brander, C ;
Walker, B .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) :451-459
[9]   Functional differences between memory and naive CD8 T cells [J].
Cho, BK ;
Wang, CY ;
Sugawa, S ;
Eisen, HN ;
Chen, JZ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2976-2981
[10]   HIV's evasion of the cellular immune response [J].
Collins, KL ;
Baltimore, D .
IMMUNOLOGICAL REVIEWS, 1999, 168 :65-74